Analysis of MRI patterns aids prediction of progression in X-linked adrenoleukodystrophy

Background: X-linked adrenoleukodystrophy (X-ALD) has variants with widely different outcomes, hampering clinical counseling and evaluation of therapies. Objective: To evaluate the degree to which MRI patterns can predict lesion progression. Methods: Two hundred six boys and men with cerebral X-ALD (median age 12.2 years, mean age 18.5 years, age range 1.7 to 73.8 years) were studied. In 140 individuals, follow-up MRI were available. Data after bone marrow transplantation (BMT) were excluded. The patterns of MRI abnormalities were subdivided into five groups based on the anatomic location of the initial T2 signal hyperintensity (pattern 1: parieto-occipital white matter, pattern 2: frontal white matter, pattern 3: corticospinal tract, pattern 4: cerebellar white matter, pattern 5: concomitant parieto-occipital and frontal white matter). The X-ALD MRI Severity Scale, a 34-point scale previously described, was used in the analysis. Results: Pattern 1 patients had rapid progression if contrast enhancement was present and if the MRI abnormality manifested at an early age. The latter was also true for pattern 2 patients. Based on these variables, predictive formulas were constructed for these two patterns using multiple regressions. MRI progression was much slower in pattern 3 and 4 patients, whereas in the few pattern 5 patients, it was more rapid than in any other of the patterns. Patterns 1 and 5 occurred mainly in childhood, patterns 2 and 4 in adolescence, and pattern 3 in adults. Conclusions: MRI progression in X-ALD depends on patient age, initial MRI Severity Scale score, and anatomic location of the lesion. When used in combination, these data aid the prediction of disease course and the selection of patients for BMT.

[1]  H. Moser,et al.  Therapy of X-linked adrenoleukodystrophy: Prognosis based upon age and MRI abnormality and plans for placebo-controlled trials , 2000, Journal of Inherited Metabolic Disease.

[2]  J. Pevsner,et al.  X-Linked Adrenoleukodystrophy: Genes, Mutations, and Phenotypes , 2004, Neurochemical Research.

[3]  H. Moser,et al.  Proton MR spectroscopic imaging predicts lesion progression on MRI in X-linked adrenoleukodystrophy , 2002, Neurology.

[4]  H. Moser,et al.  ABCD1 mutations and the X‐linked adrenoleukodystrophy mutation database: Role in diagnosis and clinical correlations , 2001, Human mutation.

[5]  H. Moser,et al.  The Dorsal Root Ganglia in Adrenomyeloneuropathy: Neuronal Atrophy and Abnormal Mitochondria , 2001, Journal of neuropathology and experimental neurology.

[6]  H. Moser,et al.  Evolution of phenotypes in adult male patients with X‐linked adrenoleukodystrophy , 2001, Annals of neurology.

[7]  H. Moser,et al.  X-Linked Adrenoleukodystrophy: Overview and Prognosis as a Function of Age and Brain Magnetic Resonance Imaging Abnormality. A Study Involving 372 Patients , 2000, Neuropediatrics.

[8]  I. Jambaqué,et al.  Long-term effect of bone-marrow transplantation for childhood-onset cerebral X-linked adrenoleukodystrophy , 2000, The Lancet.

[9]  K. Dusenbery,et al.  The worldwide hematopoietic cell transplantation experience for cerebral x-adrenoleukodystrophy , 2000 .

[10]  H. Moser,et al.  X-linked adrenoleukodystrophy: the role of contrast-enhanced MR imaging in predicting disease progression. , 2000, AJNR. American journal of neuroradiology.

[11]  H. Moser,et al.  Adrenomyeloneuropathy: A Neuropathologic Review Featuring Its Noninflammatory Myelopathy , 2000, Journal of neuropathology and experimental neurology.

[12]  H. Moser,et al.  Plasma very long chain fatty acids in 3,000 peroxisome disease patients and 29,000 controls , 1999, Annals of neurology.

[13]  J. Frahm,et al.  Quantitative Proton Magnetic Resonance Spectroscopy of Childhood Adrenoleukodystrophy , 1998, Neuropediatrics.

[14]  B. Isberg,et al.  Treatment of adrenoleukodystrophy with bone marrow transplantation , 1997, Acta paediatrica.

[15]  J. Mandel,et al.  Adrénoleucodystrophie liée à l'X , 2007 .

[16]  J. Frahm,et al.  Arrested cerebral adrenoleukodystrophy: a clinical and proton magnetic resonance spectroscopy study in three patients. , 1996, Pediatric neurology.

[17]  J. Mandel,et al.  A close relative of the adrenoleukodystrophy (ALD) gene codes for a peroxisomal protein with a specific expression pattern. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[18]  H. Moser,et al.  Multislice proton magnetic resonance spectroscopic imaging in X‐linked adrenoleukodystrophy , 1994, Annals of neurology.

[19]  H. Moser,et al.  Adrenoleukodystrophy: a scoring method for brain MR observations. , 1994, AJNR. American journal of neuroradiology.

[20]  J. Mosser,et al.  The gene responsible for adrenoleukodystrophy encodes a peroxisomal membrane protein. , 1994, Human molecular genetics.

[21]  H. Moser,et al.  The Inflammatory Myelinopathy of Adreno‐Leukodystrophy: Cells, Effector Molecules, and Pathogenetic Implications , 1992, Journal of neuropathology and experimental neurology.

[22]  C Adamsbaum,et al.  Brain MRI and electrophysiologic abnormalities in preclinical and clinical adrenomyeloneuropathy , 1992, Neurology.

[23]  J. Chaussain,et al.  MRI detects cerebral involvement in neurologically asymptomatic patients with adrenoleukodystrophy , 1989, Neurology.

[24]  Charles R.scriver,et al.  The Metabolic basis of inherited disease , 1989 .

[25]  G. di Chiro,et al.  A new CT pattern in adrenoleukodystrophy. , 1980, Radiology.